Purchase this article with an account.
Harbhajan Kaur Arora, Seena Nambiar, Manju Chandran, Geeta Menon; Effect of intravitreal Ranibizumab injections on Vitreomacular interface in patients with Age Related Wet Macular Degeneration(AMD). Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1227.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To study the effect of intravitreal Ranibizumab injections on Vitreomacular interface in patients with Age Related Wet Macular Degeneration(AMD)
We retrospectively analysed medical records and Optical coherent tomography (OCT ) scans of 27 consecutive patients (27 eyes) diagnosed with exudative AMD and receiving intravitreal Ranibizumab. The treatment consisted of 3 consecutive injections of Ranibizumab 0.5mg/0.05ml and then treated if necessary, depending on the retreatment criterion. Best corrected visual acuity (BCVA) (ETDRS),Central macular thickness (CMT), size of Vitreomacular adhesion/ traction (VMA/VMT), number of injections given were recorded and analysed at 0,3,6 and 12 months.
The mean age at presentation was 80yrs. At the end of one year mean number of injections given were 6.8. Mean BCVA (ETDRS) letters at baseline was 57.88 and showed a statistically significant improvement at 12 months by 7.12 letters (p=0.044828).Visual acuity was improved or stabilized in 22 out of 27 eyes (81%) . Baseline CMT was 334.08 micron and showed a significant reduction by 60.99 micron (p=0.018003). Mean size of VMA/VMT at baseline was 1229 micron and 1062 micron after one year. Change in size of VMA/VMT was not statistically significant (p=0.54746).During the study period out of 27 eye only 3 had spontaneous resolution 1 ( David A et al ) of VMA/VMT.
Although few cases of spontaneous resolution of VMT after Ranibizumab injection have been reported in literature2,3 (Rouvas A et al 2008, 2013) , our results with small number of patients concluded that there was no significant change in vitreomacular interface before or after getting Ranibizumab.<br /> Further prospective studies with larger group of patients receiving different kinds of anti-vascular endothelial growth factor (anti-VEGF) injections are needed to fully evaluate the effect of different kind of anti-VEGFs on Vitreomacular interface.
This PDF is available to Subscribers Only